NCT04714957 PITCHER (Peritoneal Carcinomatosis Heterogeneity)
| NCT ID | NCT04714957 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospices Civils de Lyon |
| Condition | Secondary Peritoneal Cancers |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2020-09-01 |
| Primary Completion | 2022-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2020-09-01 with a primary completion date of 2022-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
How epigenetic deregulation affects gene expression patterns in subclones of the same tumor is poorly known. Peritoneal Carcinomatosis (PC) is a condition in which multiple metastases of the same abdominal tumor develop in the peritoneal cavity and intra-peritoneal organs, thus defining different ecosystems of the same cancer. PITCHER addresses the variations in epigenetically regulated gene expression between different subclones of PC in relation with cell mechanoresponses, providing insights on how cancer epigenetic landscapes evolve under environmental pressures and on strategies used by cancer cells to adapt to the transition from one ecosystem to the other. PITCHER is a network of 10 teams from Lyon, Grenoble and Marseille, based on data and specimen collection of patients who have undergone a surgery for a peritoneal carcinomatosis of ovarian or colorectal origin. PC lesions and eventually matched specimens of primary tumors will be collected in the same patients at the time of the surgery or eventually retrieved from already existing samples. Epigenetic landscapes will be analyzed by a bioinformatics pipeline combining exome sequencing, transcriptome and methylome to identify "epigenetic hotspots", and their variations across lesions will be evaluated. These analyses will be realized in fresh (when available) or pre-existing samples. When possible, organoid cultures and animal models will be derived from multicellular structures in peritoneal fluids and membrane, cytoskeletal and nucleoskeletal mechanoresponses will be characterized using Atomic Force Microscopy. The role of tumor axonogenesis, a process of neo-formation of axon fibers in tumors, will be addressed. Experimental studies of cell responses to therapy will be performed to derive mathematical predictive models. All components will be integrated in a systems biology map of PC.
Eligibility Criteria
Inclusion Criteria: * Patients who accept to participate to the study * Men / women aged over 18 years * Patients with cancer management and care for peritoneal carcinomatosis of digestive or ovarian origin * Patients had histologic/radiologic confirmation of peritoneal disease * Serology negative HIV, HEPATITIS Exclusion Criteria: • none
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04714957 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Secondary Peritoneal Cancers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04714957 currently recruiting?
Yes, NCT04714957 is actively recruiting participants. Contact the research team at olivier.glehen@chu-lyon.fr for enrollment information.
Where is the NCT04714957 trial being conducted?
This trial is being conducted at Lyon, France.
Who is sponsoring the NCT04714957 clinical trial?
NCT04714957 is sponsored by Hospices Civils de Lyon. The trial plans to enroll 20 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.